NephRx Newsroom

November 30, 2011:   Kalamazoo, Michigan - November 30, 2011  -  NephRx Corporation today announced issuance of a new U.S. patent for its novel peptide NX002, which currently is in preclinical development for the treatment of oral mucositis and other diseases of the .... Read more

March 24, 2011:   Kalamazoo, MI – March 23, 2011 – NephRx Corporation today announced issuance of a new U.S. patent for use of its novel growth factor peptide NX002 as a potential treatment for inflammatory bowel disease (IBD).  Animal studies su .... Read more

November 18, 2010:   November 11, 2010   NephRx Corp. initiates phase I trial of its lead drug being developed for prevention of delayed graftfunction in kidney transplant patients --Company Receives Federal QTDP Grants Totaling $488,000 for Development of NX001 a .... Read more

October 21, 2010:   October 7, 2010 Sets Stage for Toxicology Studies Preparatory to Human Clinical Trials of This Novel Growth Factor Peptide NephRx Corporation today announced that a new study has shown that its novel peptide NX002 demonstrated significant efficacy when .... Read more

September 20, 2010:   NephRx makes strategic management changes to better position the Company at this critical time in the development/commercialization process James J. Koziarz named NephRx CEO. During the June, 2010 board meeting, Dr. James Koziarz was elected Preside .... Read more